-
Mashup Score: 21Attruby™ (acoramidis) Is Now Approved - Learn More - 4 day(s) ago
ATTRuby™ (acoramidis) is now approved. Access the medication guide, prescribing information, and patient support services offered through ForgingBridges
Source: attruby.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 52024 ARC Amyloidosis Community Survey - 6 day(s) ago
ARC is conducting an online survey of patients and caregivers for individuals living with amyloidosis to collect data and information on …
Source: arci.orgCategories: General Medicine News, Oncologists1Tweet-
📝 📢 Are you a physician treating #amyloidosis? ARC is conducting an anonymous online survey to collect information from patients and caregivers on their experience with diagnosis and treatment of amyloidosis. Share our survey with your patients: https://t.co/RVzr9fxpwa
-
-
Mashup Score: 8Light Chain Amyloidosis: Patient Experience Survey from the Amyloidosis Research Consortium - PubMed - 3 month(s) ago
Establishing a diagnosis of amyloidosis is difficult. Current treatments are difficult to tolerate and do not substantially improve quality of life for most patients. There is an urgent need for well-tolerated therapies with clear treatment benefit. Patient awareness of clinical trials can be improv …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, Hem/OncsTweet-
@AaronGoodman33 Unless it’s #amyloidosis….then unfortuately you’re pretty much just an average patient trying to figure out what the heck is going on with your body. https://t.co/riVH9pKe8l
-
-
Mashup Score: 26Graded Organ Response and Progression Criteria for Kidney Immunoglobulin Light Chain Amyloidosis - 4 month(s) ago
This cohort study examines graded kidney response criteria and their association with kidney and overall survival for patients with kidney light chain amyloidosis.
Source: jamanetwork.comCategories: General Medicine News, Partners & KOLsTweet-
Graded Kidney Response Criteria in AL #Amyloidosis! With improving therapies, a 30% or 50% reduction in proteinuria is no longer good enough. Impressive collaborative study by Dr. Muchtar and @MorieGertz! https://t.co/DqGkx2MrOo
-
-
Mashup Score: 55Systemic Light Chain Amyloidosis | NEJM - 4 month(s) ago
Amyloidosis, a systemic disease that manifests in various ways, should be in the differential diagnosis of unexplained proteinuria, restrictive cardiomyopathy, peripheral and autonomic neuropathy, …
Source: www.nejm.orgCategories: General Medicine News, Hem/OncsTweet-
Deeply grateful to lead and participate in the clinical trials for AL amyloidosis. Each step forward in this research represents a beacon of hope for patients. #amyloidosis @BU_Amyloidosis @NEJM Systemic Light Chain Amyloidosis https://t.co/K46p937Lu8
-
-
Mashup Score: 60Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy - 5 month(s) ago
Daratumumab’s incorporation in the upfront treatment of light chain (AL) amyloidosis has led to daratumumab (dara) refractoriness early in disease course. Patients who experience relapse or have su…
Source: www.tandfonline.comCategories: General Medicine News, Partners & KOLsTweet-
Our multicenter study led by @DimaDanai @MSHughes_MD on Venetoclax outcomes after Dara-failure in AL #Amyloidosis: VGPR rate ~90% Cardiac Organ RR~70% ~1 in 4 required another LoT at a median f/u of 22 mo. No treatment-related deaths! https://t.co/AiJHzttn4x
-
-
Mashup Score: 9Highlights from ISA 2024: the importance of early diagnosis in AL amyloidosis, trials in progress & patient selection for SCT - 5 month(s) ago
Welcome to today’s VJHemOnc podcast episode, where we will be sharing key highlights from the 2024 International Symposium on Amyloidosis…
Source: www.vjhemonc.comCategories: General Medicine News, Oncologists1Tweet-
We're pleased to share another podcast with you this week! Tune in as experts Mario Nuvolone, @vsanchorawala, @HagenPatrick81 & Efstathios Kastritis discuss the importance of early diagnosis in AL #amyloidosis, exciting trials in progress, and more! 🎧 https://t.co/iAdUM7zpYM https://t.co/o4pH1ajuq4
-
-
Mashup Score: 7ASH Clinical Practice Guidelines - 6 month(s) ago
Evidence-based clinical practice guidelines developed by ASH to help members and other practicing hematologists improve patient care. ASH also endorses other clinical guidelines of relevance to the hematology community.
Source: www.hematology.orgCategories: General Medicine News, Onc News and JournalsTweet-
The June 10 deadline to submit nominations to serve on a guideline panel is approaching! Guideline panel topics: 🩸Hydroxyurea Dosing & Monitoring for SCD 🩸Treatment of AL #Amyloidosis 🩸Iron Deficiency Anemia 🩸Immune Thrombocytopenia 🩸Myelofibrosis https://t.co/jvO1qDZkZM https://t.co/LmNah4U1Oy
-
-
Mashup Score: 5ASH Clinical Practice Guidelines - 6 month(s) ago
Evidence-based clinical practice guidelines developed by ASH to help members and other practicing hematologists improve patient care. ASH also endorses other clinical guidelines of relevance to the hematology community.
Source: www.hematology.orgCategories: General Medicine News, Onc News and JournalsTweet-
ASH invites nominations for individuals to serve on the following guideline panels: 🩸Hydroxyurea Dosing & Monitoring for SCD 🩸Treatment of AL #Amyloidosis 🩸Iron Deficiency Anemia 🩸Immune Thrombocytopenia 🩸Myelofibrosis Submit nominations by June 10: https://t.co/DlDDPE1psr https://t.co/7PdBgyXxo4
-
-
Mashup Score: 38
Not available.
Source: haematologica.orgCategories: General Medicine News, Partners & KOLsTweet-
Great to see prospective data on Dara-Vd in Stage IIIb AL #Amyloidosis! Hematologic and organ response comparable to ANDROMEDA and 2-year OS~65% (historically ~20%)! Proves that we can now successfully treat even stage IIIb! https://t.co/vvY0zqh4iR https://t.co/BR45DlmV9o https://t.co/GriqMN91Gh
-
Exciting news from @US_FDA as we have a new drug approved for #Amyloidosis. Excited for more choices for our patients @Amyloidosis_ARC @BridgeBioPharma https://t.co/FUDmo5CxOb Original data from ATTRIBUTE-CM @NEJM https://t.co/QWnSrhmVeg